Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Locate in Scotland, Scottish Trade International Move to New Office
February 19, 2001
- Average Bungyo Rate for All Programs Exceeds 40% for First Time
February 19, 2001
- Korosho Denies Need for Further Deregulation
February 19, 2001
- Sumitomo Revises Sales for 2002 Upward to \150 Billion: President Yokotsuka
February 19, 2001
- FPMAJ Drafts GL for Distinctive Labeling of Paper, Plastic Packages
February 19, 2001
- J&J Pushes Sales of Tylenol Series
February 19, 2001
- Fujisawa Aims at Top Share in Market for Psychotropics
February 19, 2001
- Guide to Prepare NDA Dossiers According to CTD Published
February 19, 2001
- Rohto to Introduce Sliming Supplement from Italy
February 19, 2001
- Santen Licenses in Anti-APO-1 Antibody from Centocor
February 19, 2001
- REGULATORY NEWS IN BRIEF -1-
February 19, 2001
- DyDo to Aggressively Expand Drugstore Business
February 19, 2001
- JT to Withdraw from OTC Business
February 19, 2001
- REGULATORY NEWS IN BRIEF -2-
February 19, 2001
- PAL Violations Found in 96 Pharmacies in 3 Years in Osaka
February 19, 2001
- Industry FTC to Ban Financial Aid for Hospitals' Social Events
February 19, 2001
- Hospitals' Income per Inpatient Down since April 2000: Survey
February 19, 2001
- Households Spent \10,865 Per Month for Healthcare in 2000
February 19, 2001
- Sales of Kampo Medicines Outdo Forecasts: Tsumura
February 19, 2001
- Number of Patients Continues to Decrease at Clinics, Dental Offices: Hodanren Survey
February 19, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…